Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Aripiprazole in Adolescent Schizophrenia and Bipolar I Disorder
NCT00102518Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Sep 2004
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aripiprazole in schizophrenia, bipolar I disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Sep 2004; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophreniabipolar I disorder
Beyond the preview
Go deeper on NCT00102518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00102518.